Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.71 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29544889 | 1.00 | KMO (0.71) | KMORECQLPOLBHSD17B10NPC1 | |
| SCHEMBL8999792 | 0.84 | KMO (0.59) | KMORECQLPOLBHSD17B10NPC1 | |
| SCHEMBL2594606 | 0.84 | KMO (0.59) | KMORECQLPOLBHSD17B10NPC1 | |
| SCHEMBL324038 | 0.83 | KMO (1.00) | KMORECQLPOLBHSD17B10TSHR | |
| SCHEMBL31427168 | 0.83 | KMO (1.00) | KMORECQLPOLBHSD17B10TSHR | |
| SCHEMBL12892436 | 0.81 | POLB (0.56) | KMORECQLPOLBHSD17B10NPC1 | |
| SCHEMBL31602336 | 0.81 | KMO (0.56) | KMORECQLPOLBHSD17B10NPC1 | |
| SCHEMBL14354840 | 0.80 | KMO (0.55) | KMORECQLPOLBHSD17B10NPC1 | |
| SCHEMBL2589000 | 0.80 | RAB9A (0.62) | KMORECQLPOLBHSD17B10NPC1 | |
| SCHEMBL22965232 | 0.80 | KMO (0.82) | KMORECQLPOLBHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112979672-B | 11, 20-dicarbonyl oridonin 14-O esterified series derivatives and application thereof | 郑州大学 | 2022-03-11 | — | — | CN | claimed |
| CN-112979672-A | 11, 20-dicarbonyl oridonin 14-O esterified series derivatives and application thereof | 郑州大学 | 2021-06-18 | — | — | CN | claimed |
| EP-1809601-B1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2014-09-10 | — | — | EP | claimed |
| JP-55038347-A | — | — | None | — | — | JP | disclosed |
| JP-55031050-A | — | — | None | — | — | JP | disclosed |
| JP-55038348-A | — | — | None | — | — | JP | disclosed |
| JP-3236361-A | — | — | None | — | — | JP | disclosed |
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4729123-A2 | COMPOSITIONS COMPRISING PRAMIPEXOLE AND A 5HT3 ANTAGONIST FOR USE IN TREATING DEPRESSION | Alto Neuroscience, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260069573-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3615024-B1 | COMPOSITIONS COMPRISING PRAMIPEXOLE AND A 5HT3 ANTAGONIST FOR USE IN TREATING DEPRESSION | ALTO NEUROSCIENCE INC (US) | 2026-02-18 | — | — | EP | disclosed |
| CN-1106368-A | Triterpene derivatives and endothelin-receptor antagonists containing the same | SHIONOGI & CO (JP) | 1995-08-09 | — | — | CN | disclosed |
| EP-0628569-A1 | Triterpene derivatives and endothelin-receptor antagonists containing the same | SHIONOGI & CO., LTD. (JP) | 1994-12-14 | — | — | EP | disclosed |
| EP-0376103-B1 | A 2-acylamino-5-halogenated-cinnamic acid derivative and method for its production | NIPPON KAYAKU KK (JP) | 1994-04-20 | — | — | EP | disclosed |
| JP-H03236361-A | 2-ACYLAMINO-5-HALOGEN-SUBSTITUTED CINNAMIC ACID DERIVATIVE AND PRODUCTION THEREOF | NIPPON KAYAKU CO LTD | 1991-10-22 | — | — | JP | disclosed |
| US-4997972-A | 2-acylamino-5-halogenated-cinnamic acid derivative and method for its production | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0376103-A1 | A 2-acylamino-5-halogenated-cinnamic acid derivative and method for its production | Nippon Kayaku Kabushiki Kaisha (JP) | 1990-07-04 | — | — | EP | disclosed |
| JP-S5538348-A | PREPARATION OF INDAZOLEACETIC ACIDS | FUJISAWA PHARMACEUT CO LTD | 1980-03-17 | — | — | JP | disclosed |
| JP-S5538347-A | PREPARATION OF INDAZOLEACETIC ACIDS | FUJISAWA PHARMACEUT CO LTD | 1980-03-17 | — | — | JP | disclosed |
| JP-S5531050-A | PREPARATION OF 1H-INDAZOLEACETIC ACID | FUJISAWA PHARMACEUT CO LTD | 1980-03-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | SLC6A3, SLC6A4, HTR4 | KMO 433/4885RECQL 4470/4885POLB 3636/4885 |
| US-20260069573-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | SLC6A3, SLC6A4, HTR4 | KMO 476/4885RECQL 3937/4885POLB 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.